Completed Clinical Trials

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

By April 24, 2017 No Comments



Estimated Enrollment: 37

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: 03-369

Study First Received: August 29, 2005

Last Updated: December 23, 2011

Estimated Primary Completion Date: March 2007


Primary Outcome Measures:

To determine the response to the combination of bevacizumab and erlotinib in previously treated malignant mesothelioma|To determine the time to tumor progression|to determine the duration of response|to determine the median and overall survival of patients|to determine the safety of the drugs administered

Sponsors and Collaborators:

Dana-Farber Cancer Institute|Massachusetts General Hospital|University of Chicago

Website Link:

Leave a Reply

Call Now ButtonCall Now